Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.
- cell or origin
- diffuse large B cell lymphoma
- double hit lymphoma
ASJC Scopus subject areas
- Clinical Biochemistry